Cardiff Oncology, Inc. $CRDF Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 67.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,974 shares of the company’s stock after purchasing an additional 68,310 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.26% of Cardiff Oncology worth $534,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Dauntless Investment Group LLC purchased a new stake in shares of Cardiff Oncology in the 1st quarter valued at $302,000. Nuveen Asset Management LLC raised its position in shares of Cardiff Oncology by 73.7% in the fourth quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company’s stock valued at $2,546,000 after buying an additional 248,850 shares during the last quarter. Laurion Capital Management LP acquired a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $2,504,000. Northern Trust Corp raised its position in shares of Cardiff Oncology by 8.9% in the fourth quarter. Northern Trust Corp now owns 337,092 shares of the company’s stock valued at $1,463,000 after buying an additional 27,489 shares during the last quarter. Finally, Millennium Management LLC increased its position in Cardiff Oncology by 188.8% during the fourth quarter. Millennium Management LLC now owns 440,944 shares of the company’s stock worth $1,914,000 after purchasing an additional 288,259 shares during the last quarter. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Price Performance

Shares of CRDF stock opened at $1.96 on Thursday. The firm’s 50-day simple moving average is $3.05 and its 200-day simple moving average is $3.24. The firm has a market cap of $130.39 million, a P/E ratio of -2.25 and a beta of 1.28. Cardiff Oncology, Inc. has a 1-year low of $1.90 and a 1-year high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. Analysts expect that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at Cardiff Oncology

In other news, Director Gary W. Pace acquired 15,000 shares of the stock in a transaction on Wednesday, July 30th. The stock was bought at an average price of $2.45 per share, with a total value of $36,750.00. Following the completion of the transaction, the director directly owned 1,345,676 shares of the company’s stock, valued at $3,296,906.20. The trade was a 1.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

CRDF has been the subject of several research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. HC Wainwright cut their price target on shares of Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. LADENBURG THALM/SH SH initiated coverage on shares of Cardiff Oncology in a research report on Tuesday, July 8th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of Cardiff Oncology in a research note on Tuesday, June 24th. They issued a “hold” rating and a $3.50 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.